Prosecution Insights
Last updated: August 17, 2026

Examiner: SHTERENGARTS, SAMANTHA L

Tech Center 1600 • Art Units: 1623 1626

This examiner grants 79% of resolved cases

Performance Statistics

79.3%
Allow Rate
+19.3% vs TC avg
1,724
Total Applications
+8.0%
Interview Lift
780
Avg Prosecution Days
Based on 1689 resolved cases, 2023–2026

Rejection Statute Breakdown

3.6%
§101 Eligibility
24.6%
§102 Novelty
14.9%
§103 Obviousness
34.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18076613 FLUORINE-CONTAINING COMPOUND Non-Final OA DAIKIN INDUSTRIES, LTD.
17446807 PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY Non-Final OA AbbVie Inc.
18558148 CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME Non-Final OA LG CHEM, LTD.
18558142 SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME Non-Final OA LG CHEM, LTD.
18557866 CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME Non-Final OA LG CHEM, LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month